Evofem Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Operations
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Net income (loss) | $(5,465) | $956 |
| Other comprehensive income: | ||
| Change in fair value of financial instruments attributed to credit risk change (Note 4) | 2,175 | 647 |
| Comprehensive income (loss) | $(3,290) | $1,603 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.